TrialReviewer
← All briefs

2026年9月5日 · 星期六

1 Key Question · 2 Research Highlights · 3 Quick Updates

Heading into the 2026–2027 respiratory season, are influenza, COVID-19, and RSV vaccines still worth getting?

According to the latest independent evidence review — yes, for those most likely to develop severe disease. An independent evidence review conducted by the Vaccine Integrity Project together with the American Medical Association (AMA) and published in JAMA as three separate papers (influenza, COVID-19, RSV) surveyed several hundred peer-reviewed studies since August 2025 and concluded that these three vaccine categories "continue to provide meaningful protection" against severe disease, hospitalization, and death, with "no new safety signals identified" in studies comparing them with currently recommended immunization schedules. Two points to read carefully: first, this is a systematic review of existing (largely observational effectiveness) evidence, not a new randomized controlled trial; the conclusion rests on "reducing severe disease/hospitalization/death," not on "blocking infection or transmission." Second, the review was undertaken as an independent stopgap against the backdrop of disruption to the routine review process of the CDC's Advisory Committee on Immunization Practices (ACIP).

JAMA（流感/新冠/RSV 三篇独立证据综述） · 2026-09-04

Who it applies to

Aimed at clinical and public health decision-making, particularly for those most likely to develop severe disease (advanced age, underlying conditions, etc.). The conclusion rests on "reducing severe disease, hospitalization, and death" and should not be extrapolated to "vaccination means you will not be infected or will not transmit."

What it showed

A systematic review of the available evidence concludes that influenza, COVID-19, and RSV immunization for the 2026–2027 season still provides meaningful protection against severe outcomes, with no new safety signals observed.

What remains unknown

The evidence synthesized in this review is largely observational vaccine effectiveness (VE) data, not new randomized evidence; for "prevention of infection/transmission" and the absolute magnitude of benefit in different populations, this briefing has not verified specific percentages item by item (gap; see checklist). As an independent stopgap following disruption to routine ACIP review, its standing differs from the previous official recommendation process, and readers should be aware of that context.

Population
Respiratory vaccination decisions for the general population and for those at high risk of severe disease; evidence drawn from several hundred peer-reviewed studies since August 2025.
Intervention
Influenza, COVID-19 (SARS-CoV-2), and RSV immunization recommended for the 2026–2027 season.
Comparator
Unvaccinated or previously recommended schedules (definitions vary across the primary studies).
Applicability
Supports the clinical and public health judgment of "vaccinating high-risk populations to reduce severe disease/hospitalization/death"; does not support the inference that "vaccination can block infection or transmission."
Primary endpoint
Outcomes of interest at the review level: severe disease, hospitalization, death; and safety signals.
Key results
All three vaccine categories continue to provide meaningful protection against severe disease/hospitalization/death; comparative studies showed no new safety signals. Effectiveness percentages by disease and by population were not verified item by item in this briefing.
Limitations
Systematic review, not a new RCT; the included evidence is largely observational effectiveness studies, with confounding and heterogeneity of design; the conclusions address severe outcomes and are not equivalent to blocking infection or transmission; as an independent assessment following disruption to ACIP review, its standing must be understood in context.
Source
Three JAMA evidence reviews + AMA/Vaccine Integrity Project official press release

Research

Worth reading this week.

ACASA-TAVI: anticoagulant monotherapy vs antiplatelet monotherapy after TAVI

Journal

Key to reading this — the primary endpoint is "subclinical leaflet thrombosis on imaging," a CT surrogate marker, not clinical stroke or death. 360 patients aged 65–80 with successful TAVI and no independent indication for anticoagulation were randomized to NOAC monotherapy (apixaban/edoxaban/rivaroxaban) or antiplatelet monotherapy (aspirin or clopidogrel) for 12 months. Leaflet thickening on CT at 12 months (subclinical thrombosis) occurred in 17.2% of the NOAC arm vs 32.6% of the antiplatelet arm (relative reduction 45%, RR 0.55, 95%CI 0.37–0.82, p=0.004); safety was non-inferior (primary safety endpoint 7.5% vs 10.6%), fatal bleeding occurred only in the antiplatelet arm, and deaths were 2 vs 10. But the sample size is clearly inadequate for hard clinical endpoints (stroke/death), and the 2 vs 10 difference in deaths cannot be taken as a conclusion about efficacy. Conclusion: NOAC monotherapy significantly reduced subclinical thrombosis on a surrogate marker without increasing bleeding — clinical benefit awaits validation in larger samples.

JAMA（ESC Congress 2026） · 替代终点阳性（临床终点未充分供能）

Diet quality and dementia risk: in older adults with existing Alzheimer pathology

Journal

An observational finding — it can speak to association only, not causation. This cohort study found that even among older adults with existing Alzheimer pathology, adherence to a dietary pattern with "lower inflammatory potential" was associated with lower dementia risk. The direction is consistent with recent MIND/anti-inflammatory diet evidence, suggesting diet may influence the window in which pathology is present but disease has not necessarily manifested. However, as an observational study, it cannot rule out reverse causation or residual confounding (people who eat healthily tend to be healthier overall); specific effect sizes such as hazard ratios were not verified from free sources for this briefing (gap; see checklist). It should not be used to make strong causal promises to individuals.

JAMA Network Open（开放获取） · 观察性关联（非因果）

Quick News

Signals worth watching.

  • Regulatory authorization · The US FDA has authorized the first robotic device capable of performing venous blood draws autonomously (a first-of-its-kind category, via the De Novo pathway with special controls). The significance lies in automating this high-frequency procedure; but "authorized for marketing" does not mean it has been shown to produce better clinical outcomes than manual blood draw across broad populations — real-world success rates and safety still require post-market data.

    Media

    FDA website · 2026-08-19

  • Cancer epidemiology · The American Cancer Society's Colorectal Cancer Statistics 2026 shows that overall colorectal cancer incidence and mortality are declining, but incidence and mortality among young adults (early-onset) continue to rise, and colorectal cancer has become an important cause of cancer death in some younger populations. These are population-level statistical trends, not individual risk prediction; they point to renewed attention to symptoms and screening age in younger populations.

    Journal

    ACS Colorectal Cancer Statistics 2026 / ASCO Post · 2026-03-01

  • Women's health · A study reports that premature menopause is associated with increased risk of later hypertension (released by The Menopause Society). This is an observational association, suggesting earlier attention to blood pressure management in this population; it does not mean premature menopause directly causes hypertension, and specific risk ratios were not verified item by item in this briefing.

    Media

    The Menopause Society press release · 2026-07-29

Sources

Every claim is traceable.